Studying Faster Ventilator
Outcomes from a Lungpacer Clinical Study Showed
Lungpacer strengthened the diaphragm and improved lung function
Positive trending clinical outcomes
These results from a randomized, controlled trial compared patients treated with Lungpacer therapy to patients treated with the standard of care. Improvement was statistically significant at p<0.05 for MIP and RSBI; p>0.05 for clinical trends. The rate of serious adverse events was the same between both groups. No unanticipated adverse device effects. Device safety events were those commonly reported for central venous catheters.